Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC

Area of Science:

• Oncology
• Precision Medicine
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) has seen significant progress with targeted therapies.
• Tyrosine kinase inhibitors (TKIs) are standard, but acquired resistance remains a major clinical challenge.
• Recent trials (ADAURA, NeoADAURA, LAURA) established osimertinib across early and advanced NSCLC stages.

Purpose of the Study:

• To review the evolving therapeutic landscape for EGFR-mutant NSCLC.
• To discuss current challenges and future directions in managing treatment resistance.
• To highlight advances in both early-stage and metastatic settings.

Main Methods:

• Review of key clinical trials and emerging therapeutic strategies.
• Analysis of combination therapies and resistance mechanisms.
• Exploration of novel agents like bispecific antibodies and antibody-drug conjugates.

Main Results:

• Osimertinib is the standard of care across NSCLC stages, but questions about adjuvant therapy duration and ctDNA-guided monitoring persist.
• Frontline combinations (osimertinib + chemotherapy, amivantamab + lazertinib) improve outcomes in metastatic EGFR-mutant NSCLC.
• Emerging strategies target resistance mechanisms like MET amplification and EGFR C797S, alongside novel drug classes.

Conclusions:

• The treatment of EGFR-mutant NSCLC is becoming increasingly personalized and adaptive to resistance.
• Optimal sequencing and combination strategies are crucial for maximizing patient benefit.
• Future research focuses on overcoming resistance to achieve durable systemic and intracranial disease control.